Telix Pharmaceuticals Ltd
ASX:TLX
Telix Pharmaceuticals Ltd
ASX:TLX
Price:
10
AUD
-1.96%
Market Closed
Market Cap:
AU$3.4B
Balance Sheet
Balance Sheet Decomposition
Telix Pharmaceuticals Ltd
Telix Pharmaceuticals Ltd
Balance Sheet Decomposition is not available for
Telix Pharmaceuticals Ltd
Telix Pharmaceuticals Ltd
Balance Sheet
Telix Pharmaceuticals Ltd
Telix Pharmaceuticals Ltd
Currency: AUD
| Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | Dec-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Cash & Cash Equivalents |
49
|
26
|
45
|
78
|
22
|
116
|
123
|
710
|
142
|
|
| Cash |
49
|
26
|
45
|
78
|
22
|
116
|
123
|
710
|
142
|
|
| Total Receivables |
0
|
8
|
13
|
14
|
21
|
30
|
49
|
100
|
138
|
|
| Accounts Receivables |
0
|
0
|
1
|
0
|
1
|
26
|
44
|
87
|
129
|
|
| Other Receivables |
0
|
0
|
12
|
14
|
20
|
4
|
5
|
13
|
9
|
|
| Inventory |
0
|
1
|
1
|
1
|
3
|
5
|
13
|
24
|
37
|
|
| Other Current Assets |
0
|
1
|
1
|
1
|
1
|
2
|
25
|
7
|
13
|
|
| Total Current Assets |
50
|
36
|
59
|
94
|
48
|
112
|
159
|
570
|
330
|
|
| PP&E Net |
0
|
0
|
2
|
5
|
6
|
12
|
21
|
34
|
116
|
|
| PP&E Gross |
0
|
0
|
2
|
5
|
6
|
12
|
21
|
34
|
116
|
|
| Accumulated Depreciation |
0
|
0
|
0
|
1
|
2
|
2
|
1
|
7
|
18
|
|
| Intangible Assets |
2
|
36
|
38
|
55
|
52
|
35
|
75
|
191
|
394
|
|
| Goodwill |
0
|
3
|
4
|
4
|
4
|
4
|
3
|
67
|
199
|
|
| Note Receivable |
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Long-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
8
|
4
|
5
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
0
|
0
|
3
|
14
|
75
|
120
|
|
| Other Assets |
0
|
3
|
4
|
4
|
4
|
4
|
3
|
67
|
199
|
|
| Total Assets |
51
N/A
|
77
+50%
|
103
+34%
|
158
+54%
|
110
-30%
|
166
+51%
|
277
+67%
|
940
+239%
|
1 164
+24%
|
|
| Liabilities | ||||||||||
| Accounts Payable |
0
|
3
|
7
|
6
|
12
|
11
|
76
|
42
|
72
|
|
| Accrued Liabilities |
0
|
0
|
0
|
0
|
11
|
21
|
10
|
47
|
52
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
1
|
0
|
1
|
1
|
0
|
1
|
13
|
19
|
|
| Other Current Liabilities |
1
|
3
|
3
|
13
|
14
|
24
|
46
|
102
|
89
|
|
| Total Current Liabilities |
1
|
8
|
11
|
20
|
38
|
55
|
111
|
205
|
232
|
|
| Long-Term Debt |
0
|
1
|
2
|
1
|
2
|
6
|
11
|
347
|
448
|
|
| Deferred Income Tax |
0
|
4
|
3
|
0
|
0
|
0
|
0
|
6
|
45
|
|
| Other Liabilities |
0
|
11
|
17
|
57
|
68
|
52
|
52
|
30
|
24
|
|
| Total Liabilities |
2
N/A
|
24
+1 222%
|
33
+37%
|
79
+142%
|
108
+37%
|
114
+6%
|
175
+54%
|
587
+236%
|
749
+27%
|
|
| Equity | ||||||||||
| Common Stock |
56
|
72
|
116
|
167
|
171
|
241
|
315
|
414
|
480
|
|
| Retained Earnings |
6
|
19
|
46
|
88
|
168
|
188
|
205
|
56
|
52
|
|
| Unrealized Security Profit/Loss |
0
|
0
|
0
|
0
|
0
|
0
|
1
|
4
|
5
|
|
| Other Equity |
0
|
0
|
0
|
0
|
1
|
0
|
7
|
2
|
7
|
|
| Total Equity |
49
N/A
|
53
+7%
|
70
+32%
|
79
+13%
|
2
-97%
|
52
+2 304%
|
103
+98%
|
353
+244%
|
415
+18%
|
|
| Total Liabilities & Equity |
51
N/A
|
77
+50%
|
103
+34%
|
158
+54%
|
110
-30%
|
166
+51%
|
277
+67%
|
940
+239%
|
1 164
+24%
|
|
| Shares Outstanding | ||||||||||
| Common Shares Outstanding |
197
|
218
|
253
|
280
|
285
|
316
|
324
|
335
|
339
|
|
Switch to:
Switch to:
See Also
Discover More
